Proteonomix, Inc. (OTCPK:PROT)
PROT, a biotechnology company, engages in the development of stem cell therapies primarily for the treatment of diabetes and cardiac therapy, as well as offers cosmeceutical products. The stem cell therapy involves the introduction of healthy new stem cells to repair and replace damaged or lost cells. It offers product for the treatment of anti-aging and damaged skin. PROT develops cosmetic products using its technologies, Secreted Matrix and Matrix NC-138 that is a stem cell derived proteins technology. PROT also involves in the operation of retail Web site, Proteoderm.com to sell its anti-aging line of skin care products; develops therapeutic modalities for the treatment of cardiovascular disease; and engages in the reproductive tissue banking, including sperm, ova, ovarian tissue, and testicular tissue. In addition, PROT develops intellectual properties for patent applications, including a medium and scaffolding for enhancing the growth of stem cells, a growth platform for stem cells, a cord blood banking cryopreservation bag, and a device to eliminate malformed stem cells via filtration. Further, PROT is developing pre-clinical-stage therapeutic agents and treatments for cancer, diabetes, heart, lung, and kidney diseases, as well as for stem cell bone marrow and organ transplants. PROT was formerly known as National Stem Cell Holding, Inc. and changed its name to Proteonomix, Inc. in August 2008. PROT was founded in 2005 and is based in Mountainside, New Jersey.
PROT, a biotechnology company focused on developing therapeutics based upon human cells and their derivatives, announced further developments with PROT's Joint Venture Company, XGEN Medical LLC towards implementing operations in the United Arab Emirates.
During initial meetings, it was mutually decided to open a local subsidiary corporation in the Dubai free zone. This wholly owned subsidiary will be the vehicle to conduct business in the GCC countries. XGen has filed the corporate papers and has established banking relations with a local bank both for receipt of the initial investment of $5 million and towards further financing expanded services in the region. The Ramadan holiday has slowed progress slightly on these corporate formalities, but full operation of the subsidiary and bank accounts are expected to complete within 30 days.
PROT CEO, Michael Cohen commented that "The business environment in the U.A.E. is very receptive to Proteonomix and our medical technologies. There is an intense focus on high quality public medical care as well as cutting edge technology. When combined with the rebounding financial condition within the region, we are very pleased to have this opportunity to conduct business in a growing location for medical advancement."
To learn more about PROT visit: http://www.proteonomix.com
Cantel Medical Corp. (NYSE:CMN)
CMN provides infection prevention and control products in the healthcare market. It operates in six segments: Water Purification and Filtration, Healthcare Disposables, Dialysis, Endoscope Reprocessing, Therapeutic Filtration, and Specialty Packaging. The Water Purification and Filtration segment provides water purification equipment and services, filtration and separation products, and disinfectants for the medical, pharmaceutical, biotech, beverage, and commercial industrial markets. The Healthcare Disposables segment offers single-use, infection control products, including face masks, towels and bibs, tray covers, saliva ejectors, germicidal wipes, plastic cups, sterilization pouches, and disinfectants used principally in the dental market. The Dialysis segment provides medical device reprocessing systems, sterilants/disinfectants, dialysate concentrates, and other supplies for renal dialysis. The Endoscope Reprocessing segment offers medical device reprocessing systems, disinfectants, enzymatic detergents, and other supplies used to clean and disinfect flexible endoscopes. The Therapeutic Filtration segment provides hollow fiber membrane filtration and separation technologies for medical applications. The Specialty Packaging segment offers specialty packaging and thermal control products, as well as related compliance training, for the transport of infectious and biological specimens and thermally sensitive pharmaceutical, and other medical products. CMN sells its products through its own direct distribution network, as well as through third-party distributors. CMN operates in the United States, Canada, Asia/Pacific, Europe, Africa, the Middle East, Latin America, and South America. CMN was founded in 1963 and is based in Little Falls, New Jersey.
CMN announced recently that Andrew A. Krakauer, President & CEO, will be presenting at the CL King 8th Annual Best Ideas Conference. The formal presentation is scheduled for 3:30 PM EDT on Wednesday, September 15, 2010 at the Omni Berkshire Place Hotel in New York City, with a Q & A session immediately following the presentation. In addition, Mr. Krakauer and Seth R. Segel, Executive Vice President, will be available for separate one-on-one meetings during the day. The presentation will be available on the Investor Relations section of CMN's website.
To learn more about CMN visit: http://www.cantelmedical.com
Charles River Laboratories International, Inc. (NYSE:CRL)
CRL is a global provider of solutions that advance the drug discovery and development process, including research models and associated services, and outsourced pre-clinical services. CRL operates through two business segments. The Research Models and Services (RMS) segment includes sales of research models, genetically engineered models and services, research animal diagnostics, discovery and imaging services, consulting and staffing services, vaccine support and in-vitro business. The Preclinical Services (PCS) segment includes services required to take a drug through the development process, including discovery support, toxicology, pathology, biopharmaceutical, bioanalysis, pharmacokinetics and drug metabolism services, as well as Phase I clinical trials. During the fiscal year ended December 26, 2009, it acquired Systems Pathology Company, LLC, Cerebricon Ltd., Piedmont Research Center LLC and Medical Supply Company, LTD.
CRL announced recently that it has implemented an accelerated stock repurchase (NYSE:ASR) program to repurchase $300 million of common stock, as part of its previously announced authorization from its Board of Directors to repurchase up to $500 million of common stock. The new ASR program will enable the Company to facilitate, on a more timely and cost efficient basis, the repurchase of a substantial number of its shares pursuant to that stock repurchase authorization.
Under the ASR program entered into with Morgan Stanley & Co. Incorporated, CRL will receive an initial delivery of 6.0 million shares. The actual number of shares that Charles River repurchases under the ASR program will be determined based on a discount to the daily volume-weighted average price (VWAP) of CRL's common stock over the course of a calculation period, which may extend approximately six months or conclude earlier at Morgan Stanley’s option. CRL intends to fund the repurchases through cash on hand and available liquidity, including its $750 million credit facility.
To learn more about CRL visit: http://www.criver.com
Chemed Corporation (NYSE:CHE)
CHE, through its subsidiaries, provides hospice care, and repair and maintenance services in the United States. CHE operates in two segments, Vitas and Roto-Rooter. The Vitas segment offers hospice services for patients with severe and life-limiting illnesses. This segment provides hospice services in routine home care, inpatient care, and continuous care. It also offers spiritual and emotional counseling to patients and their families through its team of doctors, nurses, home health aides, social workers, clergy, and volunteers. The Roto-Rooter segment provides repair and maintenance services, including plumbing and sewer, and drain and pipe cleaning to residential and commercial customers through its network of company-owned branches, independent contractors, and franchisees. CHE also manufactures and sells products and equipment used to provide such services. CHE was founded in 1970 and is based in Cincinnati, Ohio.
CHE today announced that it will deliver a presentation at CL King’s 8th Annual Best Ideas Conference on Thursday, September 16, 2010, at approximately 10 a.m. (EDT) at the Omni Berkshire Place Hotel in New York City.
The presentation will be webcast live and can be accessed through the CHE website. The webcast replay will be available within 24 hours of the live presentation and will be accessible for 90 days.
To learn more about CHE visit: http://www.chemed.com
Signup for FREE Daily Stock Alerts From CRWEFinance.com/signup
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWEFinance.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEFinance.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://crwefinance.com/disclaimer) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE) has received twenty thousand dollars in cash and twenty thousand dollars in free trading share from a third party (Swiss Financial Report) for (30) days of advertisement services for Proteonomix, Inc. (OTCPK:PROT)